 952 biologic-eligible plaque psoriasis patients captured within the study completed a selfreported questionnaire, 445 of whom were currently receiving a traditional systemic treatment without a biologic. These patients were included in subsequent analysis.
 Patient profiles were generally similar, except dissatisfied patients had higher BMI (p=0.0036) and greater % BSA (p<0.0001) compared with satisfied patients.
Patient burden associated with lack of treatment satisfaction among psoriasis patients receiving traditional systemic therapies J. O'Hara, 1 S. Lobosco, 1 G. Thompson, 2 J. Piercy 1 1 Adelphi Real World (Macclesfield, UK); 2 Janssen Cilag (Buckinghamshire, UK) Psoriasis can have a substantial impact on health-related quality of life (HRQoL) . 1 Lack of control over the disease and its symptomatology is one of the key factors in reduced HRQoL in psoriasis patients. 2 Despite the emergence of biologics as the gold standard treatment, there is evidence suggesting their uptake is limited. 3 Even among patients whose disease severity warrants the use of a biologic, many remain on a traditional systemic therapy, which may be indicative of undertreatment. 3 There is also evidence to suggest physicians may not realise the extent of the impact on patients' HRQoL 4 and patients may experience frustration with the management of their disease and perceived effectiveness of their treatment. 5 There is an emerging persuasion towards combining quality of life considerations with traditional indicators of disease severity (such as % body surface area -BSA) to drive treatment decisions, 5 which could particularly benefit moderate/severe psoriasis patients in ensuring quicker progression to more aggressive treatment regimens. 4 Systematic differences among patients in work productivity or emotional wellbeing may lead to a significant increase in societal costs, aside from the intangible costs regarding the suffering in patients and their relatives.
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Background  This analysis shows a significant difference in work productivity and emotional wellbeing among satisfied and dissatisfied biologiceligible patients currently receiving traditional systemic therapy in the absence of a biologic.
 Dissatisfied patients were more likely to be assessed as having moderate / severe disease compared with those who were satisfied.
 Dissatisfied patients also experienced greater impairment in work and regular activities and worse emotional wellbeing than those who were satisfied.
 WPAI results suggest higher societal costs which might counter the incremental cost of prescribing more expensive treatments such as biologics, although further evidence is needed to validate this.
 PHQ-9 results may indicate that patients who are less satisfied with their treatment also experience greater complications from comorbidities such as anxiety and depression  Poorer performance at work 7 and presence of higher intangible costs (e.g. suffering of patients/relatives) are not typically incorporated into formal economic evaluations.
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To investigate the proportion of patients in a biologic-eligible population currently receiving traditional systemic therapy without biologic, and to assess the burden in terms of work productivity and emotional wellbeing.
Data were drawn from the Adelphi Real World Psoriasis Disease Specific Programme (DSP), a cross-sectional survey of dermatologists and their psoriasis patients conducted in early 2011 in France, Germany, Italy, Spain and the UK. Full details of the methodology have been published previously. 6 Participating dermatologists completed a detailed patient record form (PRF) for their seven most recently seen psoriasis patients who met the inclusion criteria.
Patient inclusion criteria was based on being eligible to receive a biologic therapy; defined by BSA ever exceeding 10%, ever having moderate or severe disease (in the opinion of the physician), or ever having received a traditional systemic or biologic treatment.
Patients were invited to fill out a self-completion questionnaire independently including questions on satisfaction and validated patient-reported outcome instruments including Work Productivity and Activity Impairment (WPAI) and the Patient Health Questionnaire (PHQ-9).
Physicians and patients provided de-identified data in accordance with Health Insurance Portability and Accountability Act (HIPAA) regulations and the European Pharmaceutical Market Research Association (EphMRA) code of conduct for international healthcare market research. Responses were aggregated prior to analysis.
Patients were grouped according to their satisfaction with the level of control provided by their current treatment to identify differences in work/activity impairment and emotional wellbeing of patients satisfied and dissatisfied with their treatment regimen.
Statistical Methods: Results were tested for significance (p<0.05) using univariate analysis. Mean differences were adjusted for confounding factors (age, disease severity and % BSA) in a doubly robust estimation to support findings. To download a pdf copy please scan this QR code with your phone app reader:
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